Latest & greatest articles for ketamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ketamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ketamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ketamine

1. Ketamine for chronic pain

Ketamine for chronic pain Ketamine for chronic pain We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Ketamine for chronic pain Share: Reading time approx. 12 minutes Patients with complex and chronic pain conditions may experience that conventional pain management with for example opioids is insufficient for pain relief. Ketamine is mainly used (...) in anaesthesia, but in lower doses may also be used for pain management in the acute setting. Question What clinical evidence exists for the treatment of low-dose intravenous ketamine for chronic pain conditions? Table with identified studies Table 1. Overviews over systematic reviews Included studies Population Outcome Bell and Kalso 2018 [1] 18 systematic reviews Several populations: chronic noncancer pain, refractory cancer pain, opioid-resistant pain in palliative care, postoperative pain (chronic

2019 Swedish Council on Technology Assessement

2. Perioperative intravenous ketamine for acute postoperative pain in adults. (PubMed)

Perioperative intravenous ketamine for acute postoperative pain in adults. BACKGROUND: Inadequate pain management after surgery increases the risk of postoperative complications and may predispose for chronic postsurgical pain. Perioperative ketamine may enhance conventional analgesics in the acute postoperative setting. OBJECTIVES: To evaluate the efficacy and safety of perioperative intravenous ketamine in adult patients when used for the treatment or prevention of acute pain following (...) anaesthesia and being treated with perioperative intravenous ketamine. Studies compared ketamine with placebo, or compared ketamine plus a basic analgesic, such as morphine or non-steroidal anti-inflammatory drug (NSAID), with a basic analgesic alone. DATA COLLECTION AND ANALYSIS: Two review authors searched for studies, extracted efficacy and adverse event data, examined issues of study quality and potential bias, and performed analyses. Primary outcomes were opioid consumption and pain intensity at rest

2018 Cochrane

3. Early Administration of Ketamine in Refractory Status Epilepticus

Early Administration of Ketamine in Refractory Status Epilepticus "Early Administration of Ketamine in Refractory Status Epilepticus" by Kayla Moody < > > > > > Title Author Date of Graduation Summer 8-11-2018 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Purpose: While protocols regarding how to treat status epilepticus (SE) has been universally accepted, management of refractory status epilepticus (RSE) is far from being evidence (...) -based. Ketamine (KET), a NMDA-antagonist, may have a role in RSE when other conventional anesthetics fail due to its unique pharmacodynamic properties and good safety profile. Methods: Exhaustive search of available medical literature was performed using MEDLINE-Ovid, MEDLINE-PubMed, Psych INFO, Web of Science, and CINAHL for relevant articles from 2012-2017 using keywords “ketamine” and “status epilepticus.” Additional criteria for consideration: articles applicable to the topic and published in the English

2018 Pacific University EBM Capstone Project

4. Characteristics of patients expressing an interest in ketamine treatment: results of an online survey (PubMed)

Characteristics of patients expressing an interest in ketamine treatment: results of an online survey 30202601 2018 11 14 2056-4724 4 5 2018 Sep BJPsych open BJPsych Open Characteristics of patients expressing an interest in ketamine treatment: results of an online survey. 389-392 10.1192/bjo.2018.51 Off-label ketamine treatment has shown acute antidepressant effects that offer hope for patients with therapy-resistant depression. However, its potential for integration into treatment algorithms (...) is controversial, not least because the evidence base for maintenance treatment with repeated ketamine administration is currently weak. Ketamine is also a drug of misuse, which has raised concerns regarding the target population. Little is known about which patients would seek ketamine treatment if it were more widely available. To explore some of the characteristics of the patients actively seeking ketamine treatment. An online survey containing questions about duration of current depressive episode, number

Full Text available with Trip Pro

2018 BJPsych open

5. A Systematic Review and Meta-analysis of Ketamine as an Alternative to Opioids for Acute Pain in the Emergency Department

A Systematic Review and Meta-analysis of Ketamine as an Alternative to Opioids for Acute Pain in the Emergency Department 30019434 2018 07 18 1553-2712 2018 Jul 17 Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med A Systematic Review and Meta-analysis of Ketamine as an Alternative to Opioids for Acute Pain in the Emergency Department. 10.1111/acem.13502 Opioids are commonly prescribed in the emergency department (ED) for the treatment (...) of acute pain. Analgesic alternatives are being explored in response to an epidemic of opioid misuse. Low-dose ketamine (LDK) is one opioid alternative for the treatment of acute pain in the ED. This systematic review and meta-analysis sought to quantify whether LDK is an effective and safe opioid alternative for acute pain reduction in adults in the ED setting. (PROSPERO Registration Number CRD42017065303). This was a systematic review of randomized controlled trials comparing intravenous opioids

2018 EvidenceUpdates

6. Ketamine

Ketamine Top results for ketamine - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ketamine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

2018 Trip Latest and Greatest

7. Slow Infusion of Low-dose Ketamine Reduces Bothersome Side Effects Compared to Intravenous Push: A Double-blind, Double-dummy, Randomized Controlled Trial

Slow Infusion of Low-dose Ketamine Reduces Bothersome Side Effects Compared to Intravenous Push: A Double-blind, Double-dummy, Randomized Controlled Trial 29645317 2018 05 25 1553-2712 2018 Apr 12 Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Slow Infusion of Low-dose Ketamine Reduces Bothersome Side Effects Compared to Intravenous Push: A Double-blind, Double-dummy, Randomized Controlled Trial. 10.1111/acem.13428 We compared (...) the analgesic efficacy and incidence of side effects when low-dose (0.3 mg/kg) ketamine (LDK) is administered as a slow infusion (SI) over 15 minutes versus an intravenous push (IVP) over 1 minute. This was a prospective, randomized, double-blind, double-dummy, placebo-controlled trial of adult ED patients presenting with moderate to severe pain (numerical rating scale [NRS] score ≥ 5). Patients received 0.3 mg/kg ketamine administered either as a SI or a IVP. Our primary outcome was the proportion

2018 EvidenceUpdates

8. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management

Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management Consensus Guidelines on the Use of Intravenous Ketamine Infu... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. You currently have no recent searches Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy (...) and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Toggle navigation Articles & Issues Collections Journal Info > > Consensus Guidelines on the Use of Intravenous Ketamine Infu... Email to a Colleague Colleague's E-mail is Invalid Your Name: (optional) Your Email: Colleague's Email: Separate multiple e-mails with a (;). Message: Thought you might appreciate this item(s) I saw at Regional Anesthesia and Pain Medicine. Send a copy

2018 American Society of Regional Anesthesia and Pain Medicine

9. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain

Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain Consensus Guidelines on the Use of Intravenous Ketamine Infu... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. You currently have no recent searches Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy (...) and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Toggle navigation Articles & Issues Collections Journal Info > > Consensus Guidelines on the Use of Intravenous Ketamine Infu... Email to a Colleague Colleague's E-mail is Invalid Your Name: (optional) Your Email: Colleague's Email: Separate multiple e-mails with a (;). Message: Thought you might appreciate this item(s) I saw at Regional Anesthesia and Pain Medicine. Send a copy

2018 American Society of Regional Anesthesia and Pain Medicine

10. Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study

Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study 29700801 2018 05 19 1496-8975 65 6 2018 Jun Canadian journal of anaesthesia = Journal canadien d'anesthesie Can J Anaesth Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study. 636-646 10.1007/s12630-018-1088-0 Major depressive disorder (MDD) is a common and debilitating condition that can be challenging to treat. Electroconvulsive therapy (ECT) is (...) currently the therapeutic gold standard for treatment-resistant MDD. We tested our hypothesis that ketamine-based anesthesia for ECT results in superior improvement in treatment-resistant MDD outcomes compared with propofol-based anesthesia. Patients with treatment-resistant MDD were enrolled in a randomized clinical trial with assignment to ketamine- or propofol-based anesthesia arms. Using a modified intention-to-treat analysis, we compared the median number of ECT treatments required to achieve a 50

2018 EvidenceUpdates

11. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial 29202655 2018 01 11 1535-7228 2017 Dec 05 The American journal of psychiatry Am J Psychiatry Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. appiajp201717060647 10.1176/appi.ajp.2017.17060647 Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction (...) in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder. In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly

2018 EvidenceUpdates

12. Subcutaneous ketamine for postoperative pain relief in Rwanda: a randomized clinical trial

Subcutaneous ketamine for postoperative pain relief in Rwanda: a randomized clinical trial 29134517 2018 01 13 1496-8975 65 2 2018 Feb Canadian journal of anaesthesia = Journal canadien d'anesthesie Can J Anaesth Subcutaneous ketamine for postoperative pain relief in Rwanda: a randomized clinical trial. 170-177 10.1007/s12630-017-1009-7 Postoperative pain control is often inadequate in low-income countries such as Rwanda, prompting the search for an inexpensive improvement. A randomized (...) controlled trial was conducted to study the use of subcutaneous ketamine for the management of postoperative pain in patients undergoing major surgery in Kigali, Rwanda. Fifty-nine patients undergoing major abdominal, head and neck, plastic, or gynecological surgeries were studied. In addition to standard care, patients received five subcutaneous injections of ketamine 1 mg·kg-1 (ketamine group, n = 30) or normal saline (placebo group, n = 29) during the postoperative period. The first injection

Full Text available with Trip Pro

2018 EvidenceUpdates

13. Efficacy of Postoperative Analgesia of Local Ketamine Wound Instillation Following Total Thyroidectomy: A Randomized, Double-blind, Controlled Clinical Trial

Efficacy of Postoperative Analgesia of Local Ketamine Wound Instillation Following Total Thyroidectomy: A Randomized, Double-blind, Controlled Clinical Trial 28591084 2017 12 04 1536-5409 34 1 2018 Jan The Clinical journal of pain Clin J Pain Efficacy of Postoperative Analgesia of Local Ketamine Wound Instillation Following Total Thyroidectomy: A Randomized, Double-blind, Controlled Clinical Trial. 53-58 10.1097/AJP.0000000000000521 Total thyroidectomy is recommended as a line of management (...) of thyroid cancer in many cases. Our aim was to compare postoperative analgesic effect of local ketamine 1 mg/kg instilled in the wound to that of intramuscular (IM) ketamine and placebo after total thyroidectomy. A total of 90 patients aged 18 to 60 years, American Society of Anesthesiologists (ASA) class I to II, with a body weight of 50 to 90 kg, scheduled for total thyroidectomy were enrolled after ethics committee approval in this prospective, randomized, double-blind, controlled study and divided

2018 EvidenceUpdates

14. A Comparison of Headache Treatment in the Emergency Department: Prochlorperazine Versus Ketamine

A Comparison of Headache Treatment in the Emergency Department: Prochlorperazine Versus Ketamine 29033296 2017 10 16 1097-6760 2017 Oct 13 Annals of emergency medicine Ann Emerg Med A Comparison of Headache Treatment in the Emergency Department: Prochlorperazine Versus Ketamine. S0196-0644(17)31568-8 10.1016/j.annemergmed.2017.08.063 Intravenous subdissociative-dose ketamine has been shown to be effective for pain management, but has not been specifically studied for headaches in the emergency (...) department (ED). For this reason, we designed a study to compare standard treatment (prochlorperazine) with ketamine in patients with benign headaches in the ED. This study was a multicenter, double-blind, randomized, controlled trial with a convenience sample of patients presenting to the ED with benign headaches. Patients were randomized to receive either prochlorperazine and diphenhydramine or ketamine and ondansetron. Patients' headache severity was measured on a 100-mm visual analog scale (VAS) at 0

2017 EvidenceUpdates

15. Nasal midazolam vs ketamine for neonatal intubation in the delivery room: a randomised trial

Nasal midazolam vs ketamine for neonatal intubation in the delivery room: a randomised trial 28818854 2017 08 18 2017 08 18 1468-2052 2017 Aug 17 Archives of disease in childhood. Fetal and neonatal edition Arch. Dis. Child. Fetal Neonatal Ed. Nasal midazolam vs ketamine for neonatal intubation in the delivery room: a randomised trial. fetalneonatal-2017-312808 10.1136/archdischild-2017-312808 To compare the effectiveness of sedation by intranasal administration of midazolam (nMDZ) or ketamine (...) 9501297 1359-2998 intubation ketamine midazolam nasal mucosa newborn Competing interests: None declared. 2017 02 01 2017 05 23 2017 06 27 2017 8 19 6 0 2017 8 19 6 0 2017 8 19 6 0 aheadofprint 28818854 archdischild-2017-312808 10.1136/archdischild-2017-312808

2017 EvidenceUpdates

16. Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics? (PubMed)

Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics? 29560906 2018 12 04 2451-9030 2 7 2017 10 Biological psychiatry. Cognitive neuroscience and neuroimaging Biol Psychiatry Cogn Neurosci Neuroimaging Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics? 549-551 S2451-9022(17)30146-5 10.1016/j.bpsc.2017.08.006 Nugent Allison C AC Experimental Therapeutics and Pathophysiology Branch, National Institute

Full Text available with Trip Pro

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

17. Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment (PubMed)

Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment 29034354 2018 11 13 2451-9030 2 7 2017 Oct Biological psychiatry. Cognitive neuroscience and neuroimaging Biol Psychiatry Cogn Neurosci Neuroimaging Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment. 566-574 10.1016/j.bpsc.2017.04.006 Prefrontal global brain connectivity with global signal regression (GBCr (...) ) was proposed as a robust biomarker of depression, and was associated with ketamine's mechanism of action. Here, we investigated prefrontal GBCr in treatment-resistant depression (TRD) at baseline and following treatment. Then, we conducted a set of pharmacological challenges in healthy subjects to investigate the glutamate neurotransmission correlates of GBCr. In study A, we used functional magnetic resonance imaging ( f MRI) to compare GBCr between 22 TRD and 29 healthy control. Then, we examined

Full Text available with Trip Pro

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

18. Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders (PubMed)

Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders 28806440 2017 09 27 2018 12 07 1538-3598 318 9 2017 Sep 05 JAMA JAMA Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders. 793-794 10.1001/jama.2017.10697 Wilkinson Samuel T ST Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut. The Yale Psychiatric Hospital, Yale New Haven Health, New Haven, Connecticut. Sanacora Gerard G Department of Psychiatry, Yale School (...) of Medicine, New Haven, Connecticut. The Yale Psychiatric Hospital, Yale New Haven Health, New Haven, Connecticut. eng L30 MH111000 MH NIMH NIH HHS United States T32 MH062994 MH NIMH NIH HHS United States Journal Article United States JAMA 7501160 0098-7484 0 Anesthetics, Dissociative 690G0D6V8H Ketamine AIM IM Advisory Committees Anesthetics, Dissociative adverse effects therapeutic use Chronic Disease drug therapy Humans Ketamine adverse effects therapeutic use Mood Disorders drug therapy Off-Label Use

Full Text available with Trip Pro

2017 JAMA

19. The Use of Ketamine to Treat Suicidal Ideation

The Use of Ketamine to Treat Suicidal Ideation "The Use of Ketamine to Treat Suicidal Ideation" by Angelia C. Smith < > > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Suicide is one of the leading causes of death in the United States. Research has shown that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine can significantly decrease depressive (...) symptoms, which is a leading cause of suicidal ideation (SI). Preliminary research has shown that ketamine effectively reduces SI. The purpose of this systematic review is to expand on the current understanding of ketamine as a way to treat SI. Methods: An exhaustive search of available medical literature was preformed using OVID, Google Scholar and Web of Science. Keywords included suicide and ketamine. Quality of the eligible studies were evaluated using the Cochrane GRADE method. Results: Two

2017 Pacific University EBM Capstone Project

20. Adverse Events With Ketamine Versus Ketofol for Procedural Sedation on Adults: A Double-blind, Randomized Controlled Trial

Adverse Events With Ketamine Versus Ketofol for Procedural Sedation on Adults: A Double-blind, Randomized Controlled Trial 28493642 2017 05 11 2017 07 14 1553-2712 2017 May 11 Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Adverse Events With Ketamine Versus Ketofol for Procedural Sedation on Adults: A Double-blind, Randomized Controlled Trial. 10.1111/acem.13226 The goal of our study was to compare the frequency and severity (...) of recovery reactions between ketamine and ketamine-propofol 1:1 admixture ("ketofol"). We performed a multicentric, randomized, double-blind trial in which adult patients received emergency procedural sedations with ketamine or ketofol. Our primary outcome was the proportion of unpleasant recovery reactions. Other outcomes were frequency of interventions required by these recovery reactions, rates of respiratory or hemodynamic events, emesis, and satisfaction of patients as well as providers. A total

Full Text available with Trip Pro

2017 EvidenceUpdates